ReviewNature reviews. Nephrology2012
Management of polyomavirus-associated nephropathy in renal transplant recipients.
Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 120 citations in OpenAlex.
- Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients.Antimicrobial agents and chemotherapy · 2019Trial
- Target-specific peptides for BK virus agnoprotein identified through phage display screening: advancing antiviral therapeutics.Scientific reports · 2025Article
- Novel polyomavirus in the endangered garden dormouse Eliomys quercinus.Virology journal · 2024Article
- BK Polyomavirus in Pediatric Renal Transplantation-What We Know and What We Do Not.Biomedicines · 2024Review
- Histone deacetylase III interactions with BK polyomavirus large tumor antigen may affect protein stability.Virology journal · 2023Article
- Article
- Regulation of Virus Replication by BK Polyomavirus Small T Antigen.Journal of virology · 2023Article
- Characteristics, risk factors and outcome of BKV nephropathy in kidney transplant recipients: a case-control study.BMC infectious diseases · 2023Article
- Pretransplant BKV-IgG serostatus and BKV-specific ELISPOT assays to predict BKV infection after kidney transplantation.Frontiers in immunology · 2023Article
- Molecular characterization of BK virus detected in renal transplant patients in Sri Lanka: a preliminary study.The Indian journal of medical research · 2022Article
- Article
- Endoplasmic Reticulum Stress Mediates Renal Tubular Vacuolation in BK Polyomavirus-Associated Nephropathy.Frontiers in endocrinology · 2022Article
- Conversion from mycophenolate mofetil to mizoribine in the early stages of BK polyomavirus infection could improve kidney allograft prognosis: a single-center study from China.BMC nephrology · 2021Article
- Non-permissive human conventional CD1c+ dendritic cells enable trans-infection of human primary renal tubular epithelial cells and protect BK polyomavirus from neutralization.PLoS pathogens · 2021Article
- Control of Archetype BK Polyomavirus MicroRNA Expression.Journal of virology · 2020Article
- Identification of a new strain of mouse kidney parvovirus associated with inclusion body nephropathy in immunocompromised laboratory mice.Emerging microbes & infections · 2020Article
- Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic.Clinical journal of the American Society of Nephrology : CJASN · 2020Article
- Glibenclamide inhibits BK polyomavirus infection in kidney cells through CFTR blockade.Antiviral research · 2020Article
- Article
- BK Virus Nephropathy: Prevalence, Impact and Management Strategies.International journal of nephrology and renovascular disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Polyomavirus-associated nephropathy (PVAN) remains an important infectious complication after renal transplantation, affecting 1-10% of recipients and causing graft loss in approximately 50% of cases. With the lack of effective antiviral therapy, intensive monitoring for BK virus (BKV) using nucleic acid testing or urine cytology--in combination with a reduction of immunosuppressive therapy--is advocated to detect and prevent BKV reactivation and PVAN, respectively. In this Review, new insights into BKV biology and the development of PVAN are discussed. Clinical diagnostic approaches for the detection, surveillance and therapeutic monitoring of BKV are described. In addition, various strategies for reduction of immunosuppressive therapy are reviewed and an evaluation provided of the mechanisms of action and clinical effects of currently used adjuvant medication such as cidofovir, leflunomide, intravenous immunoglobulins and fluoroquinolone antibiotics. Finally, novel compounds and their in vitro actions against BKV are discussed together with future prospects for specific antiviral drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.